Palbociclib has 31 known drug interactions based on U.S. FDA drug labeling data. 20 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Clarithromycin, Enzalutamide. Patients taking Palbociclib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 31
- Major
- 20
- Moderate
- 11
Major (20)
- Palbociclib + Carbamazepine— Strong CYP3A inducer. Avoid concomitant use with palbociclib.
- Palbociclib + Clarithromycin— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Enzalutamide— Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wo…
- Palbociclib + Grapefruit Juice— Avoid grapefruit or grapefruit juice during palbociclib treatment due to CYP3A inhibition.
- Palbociclib + Indinavir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Itraconazole— ( 7.3 ) 7.1 Agents That May Increase Palbociclib Plasma Concentrations Effect of CYP3A Inhibitors Coadministration of a …
- Palbociclib + Ketoconazole— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Lopinavir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Lopinavir And Ritonavir— Strong CYP3A inhibitor. Avoid concomitant use or reduce palbociclib dose if unavoidable.
- Palbociclib + Nefazodone— Strong CYP3A inhibitor. Avoid concomitant use or reduce palbociclib dose if unavoidable.
- Palbociclib + Nelfinavir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Phenytoin— Strong CYP3A inducer. Avoid concomitant use with palbociclib.
- Palbociclib + Posaconazole— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Rifampin— Strong CYP3A inducer decreases palbociclib plasma exposure by 85%. Avoid concomitant use.
- Palbociclib + Ritonavir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Saquinavir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + St. John'S Wort— Strong CYP3A inducer. Avoid concomitant use with palbociclib.
- Palbociclib + Telaprevir— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Telithromycin— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
- Palbociclib + Voriconazole— Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir…
Moderate (11)
- Palbociclib + Alfentanil— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Cyclosporine— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Dihydroergotamine— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Ergotamine— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Everolimus— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Fentanyl— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Midazolam— Palbociclib increases midazolam plasma exposure by 61%. Monitor and consider dose reduction of midazolam.
- Palbociclib + Pimozide— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Quinidine— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Rapamycin— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.
- Palbociclib + Tacrolimus— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.